Capabilities by Industry: Healthcare
Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector. Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe, Australia and Japan have executed many of the most significant and complex transactions for some of the leading companies in the industry.
In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.
Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals; and biotechnology.
Below we highlight a few of the transactions on which we have advised in this area:
Recent Transactions
Sort By
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Concordia International Corp.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
MorphoSys AG
![China China flag](https://www.greenhill.com/sites/default/files/china.gif)
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
![South Africa/Switzerland South Africa, Switzerland flags](https://www.greenhill.com/sites/default/files/s-africa_switz_91006.gif)
Hirslanden Private Hospital Group
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Radiogroup Participações S.A.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
![Saudi Arabia Saudi Arabia Flag](https://www.greenhill.com/sites/default/files/saudiarabia.gif)
Equity stake in Bupa Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Derma Sciences, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Palatin Technologies, Inc. lead product candidate, Rekynda
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
![USA/Canada U.S.A., Canada flags](https://www.greenhill.com/sites/default/files/usa_canada.gif)
Concordia International Corp
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
![UK/Ireland U.K., Ireland flags](https://www.greenhill.com/sites/default/files/uk-ireland_35558.gif)
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
BioD, LLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to an authorized generic version of Adderall XR
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 37 approved and 5 pipeline generic products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aegerion Pharmaceuticals
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Total Care Medicaid Plan
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan